All News

The third-gen PCKS9 inhibitor was approved in December 2025 as adjunctive treatment alongside diet and exercise for adults with hypercholesterolemia.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

A national survey finds retina specialists tolerate higher GA treatment risks in exchange for greater lesion growth rate reduction.

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

This meta-analysis encompassed 18 studies published through December 31, 2025.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.

Clinicians spotlight issues that stall pediatric atopic dermatitis escalation and biologic therapy access, despite worsening disease burden.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

A narrative review links IL-17 signaling to metabolic syndrome and cardiovascular risk in psoriasis, though hard-outcome trial data remain limited.

Employers with complete claims data access deploy more cost-containment strategies as health care costs rise and employers seek greater PBM transparency.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

Trump's vaccine executive order calls for fewer routine childhood vaccines and changes to MMR, raising questions about coverage, access, and vaccine uptake.

Most Medicare beneficiaries with ATTR-CM waited more than 6 months for diagnosis after heart failure onset, with longer delays among women.

HHS announced proposed FDA changes to GRAS oversight and a proposed definition of ultra-processed foods as part of the MAHA agenda.

The BTK inhibitor also showed fewer severe adverse events and better patient-reported quality of life than chemoimmunotherapy.

Obesity may independently worsen psoriasis severity and blunt response to fixed-dose biologics, prompting calls for weight-adapted treatment selection.

Extreme heat may accelerate plastic breakdown and increase microplastic exposure, with potential CV, endocrine, and skin health effects, said Eva R. Parker, MD.

Bipartisan Senate bill would codify 340B patient rules, end rebate model, boost oversight—as CMS separately proposes deep Medicare 340B payment cuts.

A retrospective study of 76 patients at a Spanish allergy clinic found occupational exposure suspected in more than half of chronic hand eczema cases, with patch testing tying most sensitizations to preservatives, nickel, and rubber accelerants.